DarioHealth Corp. — FY2017 Form 10-K Summary
Reporting period: Fiscal year ended December 31, 2017. This is an annual filing; the supplied text does not provide a separate fourth-quarter income statement.
Business context
DarioHealth develops and sells a connected diabetes-management system comprising a smartphone-linked glucose meter, app, test strips and related consumables. Revenue was generated primarily from product sales, including direct-to-consumer sales and distributor channels. Dario Engage had been launched, while Dario Intelligence remained a planned analytics offering.
Financial performance and position
| Metric (US$ millions, except per-share data) | 2017 | 2016 |
|---|---|---|
| Revenue | 5.170 | 2.803 |
| Gross profit (loss) | 1.311 | (0.830) |
| Operating expenses | 15.730 | 10.271 |
| Operating loss | 14.419 | 11.101 |
| Net loss | 15.743 | 10.887 |
| Cash used in operating activities | 10.619 | 8.379 |
| Cash and cash equivalents at year-end | 3.718 | 1.093 |
| Current assets / current liabilities | 6.046 / 3.015 | 2.936 / 2.925 |
| Stockholders’ equity (deficiency) | 3.941 | (6.541) |
Revenue increased about 84% year over year. Gross margin was approximately 25% in 2017, compared with a gross loss in 2016. The reported 2017 loss included $1.168 million of warrant revaluation expense; 2016 included $0.260 million of warrant revaluation income. Basic and diluted loss per share was $1.64 in 2017 versus $2.09 in 2016.
Cash provided by financing was $13.463 million in 2017, principally from securities offerings. Investing activities used $0.219 million. No conventional borrowing balance is shown in the supplied balance sheet; reported liabilities included $3.015 million of current liabilities and a $0.001 million warrant liability at year-end. Accumulated deficit was $70.958 million.
Changes, outlook and risks
- Operating expenses rose to $15.730 million: sales and marketing increased to $7.707 million, R&D to $3.297 million and G&A to $4.726 million. Management attributed marketing growth mainly to digital campaigns, especially in the U.S. and Australia.
- Management estimated existing resources would support planned activity only into March 2019, assuming forecast sales inflows. The auditor highlighted substantial doubt about the Company’s ability to continue as a going concern. Additional financing may be needed sooner if sales or funding fall short.
- After year-end, the Company reported private placements with approximately $6.623 million gross proceeds (approximately $6.048 million net), plus warrants; conversion of preferred shares was subject to stockholder approval. These transactions may affect dilution and liquidity.
- Commercial developments included FDA 510(k) clearance for certain Android devices in September 2017, a German online store launch, and commencement of Australian sales of the Lightning-connector version in January 2018. The Company planned to pursue U.S. clearance for that version and expand Dario Engage partnerships; no quantified revenue or earnings guidance is provided.
- Key risks include continued losses and cash burn, reliance on further financing, limited commercial history, competition from established glucose-monitor companies, dependence on third-party manufacturers and distributors, reimbursement uncertainty, regulatory requirements, and privacy and data-protection obligations.
- Unusual items included warrant-liability remeasurement and reclassification, substantial equity issuance and stock-based compensation. The filing reports $3.824 million of stock-based compensation in 2017. The 2016 production-line impairment was $0.269 million; no impairment was recorded in 2017.
- Data inconsistency: MD&A states 2016 cost of revenue was $3.633 million, while the audited statements show $3.364 million. The audited statements also report 2016 gross loss of $0.830 million, including a separate $0.269 million production-line impairment.
Important facts for investors to verify
- Reconcile the conflicting 2016 cost-of-revenue figures and confirm the audited financial-statement amounts.
- Review the auditor’s going-concern discussion and assess whether post-year-end financing and actual sales extend the stated runway.
- Examine the terms, share-conversion approvals and warrant dilution from the 2018 financing, alongside other outstanding warrants and equity awards.
- Track revenue growth, gross margins, operating cash burn, customer retention and recurring consumables sales to assess commercial traction.
- Verify regulatory status and reimbursement coverage by market, and adoption and revenue contribution from Dario Engage; Dario Intelligence remained a future plan.